Biological and targeting differences between the rare KRAS A146T and canonical KRAS mutants in gastric cancer models.

Elisabetta PuligaChiara De BellisSandra Vietti MichelinaTania CapeloaCristina MiglioreClaudia OrrùGian Luca BaiocchiGiovanni De ManzoniFilippo PietrantonioRossella ReddavidUberto Fumagalli RomarioChiara AmbrogioSimona CorsoSilvia Giordano

Published in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2024)

A deeper genomic and biological characterization of KRAS mutants might sustain the development of more efficient and long-lasting therapeutic options for patients harbouring KRAS-driven GC.

Keyphrases

wild type
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
prognostic factors
peritoneal dialysis
cancer therapy
drug delivery
dna methylation
copy number
high resolution